Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Gains from Sales and Divestitures (2020 - 2025)

Moleculin Biotech's Gains from Sales and Divestitures history spans 6 years, with the latest figure at $3730.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $3730.0 for Q4 2025, down 86.36% from a year ago — trailing twelve months through Dec 2025 was $3730.0 (down 86.36% YoY), and the annual figure for FY2025 was $3730.0, down 86.36%.
  • Gains from Sales and Divestitures for Q4 2025 was $3730.0 at Moleculin Biotech, down from $27348.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $65421.0 in Q4 2022 to a low of $3730.0 in Q4 2025.
  • The 5-year median for Gains from Sales and Divestitures is $27348.0 (2024), against an average of $27264.6.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 134.29% in 2022, then crashed 86.36% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $27923.0 in 2021, then skyrocketed by 134.29% to $65421.0 in 2022, then crashed by 81.81% to $11901.0 in 2023, then soared by 129.8% to $27348.0 in 2024, then crashed by 86.36% to $3730.0 in 2025.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $3730.0, $27348.0, and $11901.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.